- Home
- KLRS vs BOLD Comparison
KLRS vs BOLD Comparison
Compare KLRS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- BOLD
- Stock Information
- Founded
- KLRS 2019
- BOLD 2018
- Country
- KLRS United States
- BOLD United States
- Employees
- KLRS N/A
- BOLD N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- BOLD
- Sector
- KLRS Health Care
- BOLD
- Exchange
- KLRS Nasdaq
- BOLD Nasdaq
- Market Cap
- KLRS 57.5M
- BOLD 49.5M
- IPO Year
- KLRS N/A
- BOLD 2024
- Fundamental
- Price
- KLRS $8.60
- BOLD $1.67
- Analyst Decision
- KLRS
- BOLD Buy
- Analyst Count
- KLRS 0
- BOLD 3
- Target Price
- KLRS N/A
- BOLD $22.50
- AVG Volume (30 Days)
- KLRS 20.1K
- BOLD 87.9K
- Earning Date
- KLRS 05-15-2025
- BOLD 03-27-2025
- Dividend Yield
- KLRS N/A
- BOLD N/A
- EPS Growth
- KLRS N/A
- BOLD N/A
- EPS
- KLRS N/A
- BOLD N/A
- Revenue
- KLRS N/A
- BOLD N/A
- Revenue This Year
- KLRS N/A
- BOLD N/A
- Revenue Next Year
- KLRS N/A
- BOLD N/A
- P/E Ratio
- KLRS N/A
- BOLD N/A
- Revenue Growth
- KLRS N/A
- BOLD N/A
- 52 Week Low
- KLRS $7.96
- BOLD $1.42
- 52 Week High
- KLRS $24.15
- BOLD $14.72
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- BOLD N/A
- Support Level
- KLRS N/A
- BOLD N/A
- Resistance Level
- KLRS N/A
- BOLD N/A
- Average True Range (ATR)
- KLRS 0.00
- BOLD 0.00
- MACD
- KLRS 0.00
- BOLD 0.00
- Stochastic Oscillator
- KLRS 0.00
- BOLD 0.00
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.